Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
VANCOUVER, British Columbia, April 25, 2017 -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the Bloom Burton & Co. Healthcare Investor Conference in Toronto. Chief Executive Officer Mary Szela is scheduled to present on Monday, May 1, 2017 at 10:00 a.m. EDT.
The presentation will be webcast live and may be accessed for up to 90 days following the conference by visiting the “Investors” section of Novelion’s website, www.novelion.com.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
